MSB 0.00% $1.10 mesoblast limited

Cell Therapy News/Articles, page-13671

  1. 3,879 Posts.
    lightbulb Created with Sketch. 1317
    You call it a risk, why?
    My point is that with the data we have you cannot conclude that patients progressed to class 3. More likely given comments made, controls did not progress. This would then mean that the treated population did not progress either .
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.